ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: Distribution and impact on survival

Journal of Thoracic Oncology

Volumn 5, Issue 4, 2010, Pages 453-459

  Skov, Birgit Guldhammer ^a   Holm, Bente ^a   Erreboe, Anders ^a   Skov, Torsten ^b   Mellemgaard, Anders ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Department of Oncology Herlev Hospital ^*  (Denmark)

Author keywords

Carcinoids; ERCC1; Ki67; Large cell neuroendocrine carcinoma; Small cell lung cancer; Survival

Indexed keywords

CARBOPLATIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; KI 67 ANTIGEN; PLATINUM; TOPOTECAN; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARCINOID; CLINICAL FEATURE; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS;

EID: 77950996012     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ca063b     Document Type: Article

References (53)

1. Ferraldeschi R, Baka S, Jyoti B, et al. Modern management of small-cell lung cancer. Drugs 2007;67:2135-2152. (Pubitemid 47557091)
2. Amarasena IU, Walters JA, Wood-Baker R, et al Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev 2008;4:CD006849.
3. Cooper WA, Thourani VH, Gal AA, et al. The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest 2001;119:14-18.
4. Filosso PL, Rena O, Donati G, et al. Bronchial carcinoid tumors: surgical management and long-term outcome. J Thorac Cardiovasc Surg 2002;123:303-309. (Pubitemid 34127118)
5. Thomas CF Jr, Tazelaar HD, Jett JR. Typical and atypical pulmonary carcinoids: outcome in patients presenting with regional lymph node involvement. Chest 2001;119:1143-1150.
6. Cardillo G, Sera F, Di MM, et al. Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg 2004;77: 1781-1785. (Pubitemid 38530025)
7. Zacharias J, Nicholson AG, Ladas GP, et al. Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection. Ann Thorac Surg 2003;75:348-352. (Pubitemid 36184468)
8. Veronesi G, Morandi U, Alloisio M, et al. Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer 2006;53:111-115. (Pubitemid 43831353)
9. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33:9-23. (Pubitemid 46137553)
10. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008;14:1291-1295. (Pubitemid 351413906)
11. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991. (Pubitemid 44343542)
12. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-808. (Pubitemid 46294612)
13. Azuma K, Komohara Y, Sasada T, et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 2007;98:1336-1343. (Pubitemid 47241754)
14. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-2291. (Pubitemid 34753602)
15. Holm B, Mellemgaard A, Skov T, et al. Different impact of ERCC1 on survival in male and female patients with inoperable non-small cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol 2009;27: 4254-4259.
16. Booton R, Ward T, Ashcroft L, et al. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2007;2:902-906. (Pubitemid 47511592)
17. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007;25:2741-2746. (Pubitemid 47123182)
18. Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS ONE 2009;4:e5133.
19. Lee HW, Han JH, Kim JH, et al. Expression of excision repair crosscomplementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 2008;59:95-104.
20. Ceppi P, Longo M, Volante M, et al. Excision repair cross complementing- 1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study. J Thorac Oncol 2008;3:583-589. (Pubitemid 351787300)
21. Kim YH, Ishii G, Goto K, et al. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer 2009;65:105-111.
22. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998;22:934-944. (Pubitemid 28364493)
23. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973;4:31-42.
24. Mountain CF. Revisions in the International system for staging lung cancer. Chest 1997;111:1710-1717. (Pubitemid 27260107)
25. Skov BG, Krasnik M, Lantuejoul S, et al. Reclassification of neuroendocrine tumors improves the separation of carcinoids and the prediction of survival. J Thorac Oncol 2008;3:1410-1415.
26. Dingemans AM, Witlox MA, Stallaert RA, et al. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res 1999;5:2048-2058.
27. Shimizu J, Horio Y, Osada H, et al. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology 2008;13:510-517. (Pubitemid 351725293)
28. Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 2006;24:2158-2163. (Pubitemid 46630688)
29. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91. (Pubitemid 34438898)
30. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/ cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-2535.
31. Guichard S, Arnould S, Hennebelle I, et al. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. Anticancer Drugs 2001;12:741-751. (Pubitemid 33001188)
32. Zeghari-Squalli N, Raymond E, Cvitkovic E, et al. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 1999;5:1189-1196. (Pubitemid 29233237)
33. Liu C, Zhou S, Begum S, et al. Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer. Lung Cancer 2007;55:303-311. (Pubitemid 46329184)
34. Taillade L, Penault-Llorca F, Boulet T, et al. Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 2007;18:1043-1050. (Pubitemid 47050496)
35. Viberti L, Papotti M, Abbona GC, et al. Value of Ki-67 immunostaining in preoperative biopsies of carcinomas of the lung. Hum Pathol 1997; 28:189-192. (Pubitemid 27069185)
36. Bozzetti C, Franciosi V, Crafa P, et al. Biological variables in non-small cell lung cancer: comparison between immunocytochemical determination on fine needle aspirates from surgical specimens and immunohistochemical determination on tissue sections. Lung Cancer 2000;29:33-41. (Pubitemid 30398557)
37. Meert AP, Martin B, Verdebout JM, et al. Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. Lung Cancer 2004;44:295-301. (Pubitemid 38609437)
38. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127:978-983. (Pubitemid 40775532)
39. Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-232.
40. Roy MS, Yoshizawa A, Fukuoka J, et al. High ERCC1 expression correlates with poor survival in lung adenocarcinomas. J Thorac Oncol 2007;2:S423.
41. Fleischmann A, Schlomm T, Huland H, et al. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res 2008;14:7838-7842.
42. Travis WD, Brambilla E, Muller-Harmelink HK, et al. Tumors of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC, 2004.
43. Dahia PL, Aguiar RC, Honegger J, et al. Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Oncogene 1998;16:69-76. (Pubitemid 28043509)
44. Capella C, Heitz PU, Hofler H, et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995; 425:547-560.
45. Canavese G, Azzoni C, Pizzi S, et al. p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior. Hum Pathol 2001;32:1094-1101. (Pubitemid 33015670)
46. Costes V, Marty-Ane C, Picot MC, et al. Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67-labeling study. Hum Pathol 1995;26:740-745.
47. Bohm J, Koch S, Gais P, et al. Prognostic value of MIB-1 in neuroendocrine tumours of the lung. J Pathol 1996;178:402-409. (Pubitemid 26146796)
48. Laitinen KL, Soini Y, Mattila J, et al. Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity. Cancer 2000;88:1590-1598. (Pubitemid 30183144)
49. Lin O, Olgac S, Green I, et al. Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms. Am J Clin Pathol 2003;120:209-216. (Pubitemid 37046355)
50. Rugge M, Fassan M, Clemente R, et al. Bronchopulmonary carcinoid: phenotype and long-term outcome in a single-institution series of Italian patients. Clin Cancer Res 2008;14:149-154. (Pubitemid 351377990)
51. Vilar E, Salazar R, Perez-Garcia J, et al. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 2007;14:221-232. (Pubitemid 47242624)
52. Brambilla E, Negoescu A, Gazzeri S, et al. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996;149:1941-1952. (Pubitemid 26415213)
53. Beasley MB, Lantuejoul S, Abbondanzo S, et al. The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol 2003;34:136-142 (Pubitemid 36258804)